> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alkermes Gets Fast Track on Ovarian Cancer Therapy
- URL: https://www.fdaweb.com/alkermes-gets-fast-track-on-ovarian-cancer-therapy/
- Published: 2021-10-25T12:00:00.000Z
- Updated: 2026-09-14T17:20:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150436

FDA has granted Alkermes a fast track designation for nemvaleukin alfa, an engineered interleukin-2 (IL-2) variant immunotherapy for use in combination with Merck’s Keytruda (pembrolizumab) in treating platinum-resistant ovarian cancer. Alkermes says nemvaleukin is designed to “preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex.” The agency previously granted nemvaleukin fast track status and an orphan drug designation for treating mucosal melanoma.